2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster III

Program: Poster Abstract Session
Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Antibody Therapy, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Radiation Therapy, Adverse Events, Artificial Intelligence (AI), Deep Learning, Biological Processes, Genomics, Hematopoiesis, Immune Mechanism, Microbiome, Molecular Biology, Diseases, Immunology, Autoimmune Disorders, Immunodeficiency, Infectious Diseases, Viral, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, CML, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Health Disparities Research, Real-World Evidence, Study Population, Human, Adult, Elderly, Young Adult, Animal Model
PAPER

5864 Prevention of CAR-T cell exhaustion by glycocalyx engineering prolongs survival in a relapsed lymphoma model in vivo

Elliot C Woods, MD, PhD, Sangwoo Park2, Elijah Darnell3, Cassiddy Ho4, Lauren Pepi, PhD5, Marcela V. Maus, MD, PhD6, Russell W Jenkins, MD, PhD7, Nir Hacohen, PhD8
1 Massachusetts General Hospital, Boston, Massachusetts, United States
2 Massachusetts General Hospital, Boston, Massachusetts, United States
3 Massachusetts General Hospital, Boston, Massachusetts, United States
4 Massachusetts General Hospital, Boston, Massachusetts, United States
5 Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
6 Massachusetts General Hospital, Boston, Massachusetts, United States
7 MUSC Hollings Cancer Center Pharmacy, Charleston, South Carolina, United States
8 Massachusetts General Hospital, Boston, Massachusetts, United States

At the heart of the success of immunotherapies in the treatment of malignancies are cell-cell interactions. While greater attention is gathering onto tumor-side glycobiology involved in these interactions, surprisingly little is understood about the role of glycans in immune cell function. Because T-cell exhaustion is a major driver of CAR-T cell relapse in B-cell malignancies, we sought to explore the possible role of glycans in T-cell function. Herein, we discovered that as T-cells progress from naïve to activated to exhausted, they increasingly express the α2,3-sialic acid-containing ganglioside GM3. We found that GM3 acts as a modulator of T-cell activation and exhaustion and that CAR-T cells overexpressing GM3 were more resistant to exhaustion and prolonged survival in a murine model of relapsed lymphoma compared to standard of care (SOC) CAR-T cells.

We utilized lectin-based flow cytometry to characterize glycans as peripheral CD8+ T-cells from healthy donors progressed from naïve to activated to exhausted through a CD3/CD28 costimulatory bead chronic stimulation protocol in the presence of IL-2 across 5-6 stimulations over 12-14 days. Regardless of donor, terminal α2,6-linked sialic acids were abundant from start to finish, but α2,3-linked sialic acids started at very low levels and steadily increased throughout the duration of the experiment. Published RNA-seq data confirmed for us that the genes responsible for α2,3 sialic acid elaboration are indeed overexpressed in exhausted T-cells from primary human tumors, confirming the results of our in vitro exhaustion model. To determine whether these sialic acids affect T-cell function, we performed live-cell imaging assays of CAR-T cell killing with or without prior sialidase digestion. CAR-T cells treated with sialidase showed significantly more rapid killing kinetics across various donors and ET ratios. They also produced more cytotoxic cytokines per cell than their untreated counterparts suggesting a greater extent of activation.

To identify the molecular species bearing these α2,3 sialic acids, we performed substrate-agnostic glycomics and identified the ganglioside GM3 as the dominant sialic acid containing species distinguishing naïve from exhausted T-cells. After confirming with a GM3-specific antibody that the ganglioside follows the same pattern seen with the lectin flow cytometry – very low initially with a steady increase from naïve to activated to exhausted, and that GM3 is indeed cleaved by sialidase in our CAR-T cell activity assays, we sought to isolate the structure-function relationship of the GM3 ganglioside in tumor-immune interactions. We utilized CRISPR-Cas9 to knock-out ST3GAL5 (GM3-KO), the terminal and rate-limiting enzyme in GM3 synthesis, in CAR-T cells and simultaneously built an ST3GAL5 overexpressing CAR construct. In vitro, GM3-KO CAR-T cells kill more rapidly across several donors, and ST3GAL5 overexpression (OE) leads to slower killing kinetics. However, despite this acute activating phenotype leading to faster initial kinetics, we also found that in our model of chronic stimulation GM3 expression conferred an inverse relationship to the emergence of exhaustion markers – GM3-KO CAR-T cells exhausted more rapidly than control CAR-T cells and ST3GAL5 OE slowed the emergence of exhaustion. Thus, after chronic stimulation, ST3GAL5 OE CAR-T cells showed the most robust tumor killing in vitro compared to control SOC CAR-T cells or GM3-KO CAR-T cells, confirming that GM3 may act as a brake against overactivation of T-cells and may prevent the emergence of an exhaustion phenotype. We confirmed these findings across multiple T-cell donors.

To test this hypothesis in a more physiologic model, we utilized a relapsed in vivo model of B-cell lymphoma in which mice are ‘rechallenged’ with tumor after initial treatment without reintroduction of CAR-T cells to assess durability of the initial treatment. Mice initially treated with control SOC CAR-T cells or GM3-KO CAR-T cells were unable to overcome this second challenge (n=5 each), with mortality inversely related to GM3 expression, whereas GM3-enriched ST3GAL5-OE CAR-T cells conferred lasting protection against this rechallenge with all mice surviving ‘relapse’ of the tumors and eliminating them (n=5). Our findings highlight the complex biology at play in the glycans of the tumor-immune synapse and reveal glycocalyx engineering as a strategy for improving CAR-T cell persistence in relapsed lymphoma.

Elliot C Woods, MD, PhD: Valora Therapeutics Inc. - Consultancy (Includes expert testimony); Palleon Pharmaceuticals Inc. - Consultancy (Includes expert testimony)